Antidepressant mechanism of ketamine: Perspective from preclinical studies

Frontiers in Neuroscience

Volumn 9, Issue JUL, 2015, Pages

  Scheuing, Lisa ^a   Chiu, Chi Tso ^a   Liao, Hsiao Mei ^a   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

GSK 3 inhibitor; Ketamine; Lithium; Major depressive disorder; MTOR; NMDA antagonist; Therapeutic potential

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; KETAMINE; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN;

ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; BIPOLAR DISORDER; COMPARATIVE EFFECTIVENESS; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; MAJOR DEPRESSION; NEUROPROTECTION; NONHUMAN; PREFRONTAL CORTEX; PROTEIN TARGETING; RECEPTOR BLOCKING; SCHIZOPHRENIA; SHORT SURVEY; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; TREATMENT INDICATION;

EID: 84938539210     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00249     Document Type: Short Survey

References (68)

1. Aan Het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., et al. (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 67, 139-145. doi: 10.1016/j.biopsych.2009.08.038.
2. Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P. F., et al. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91-95. doi: 10.1038/nature10130.
3. Autry, A. E., and Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 64, 238-258. doi: 10.1124/pr.111.005108.
4. Bechtholt-Gompf, A. J., Smith, K. L., John, C. S., Kang, H. H., Carlezon, W. A. Jr., Cohen, B. M., et al. (2011). CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacol. (Berl). 215, 689-695. doi: 10.1007/s00213-011-2169-8.
5. Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354. doi: 10.1016/S0006-3223(99)00230-9.
6. Beurel, E., Grieco, S. F., and Jope, R. S. (2015). Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther. 148, 114-131. doi: 10.1016/j.pharmthera.2014.11.016.
7. Beurel, E., Song, L., and Jope, R. S. (2011). Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol. Psychiatry 16, 1068-1070. doi: 10.1038/mp.2011.47.
8. Burgdorf, J., Zhang, X. L., Nicholson, K. L., Balster, R. L., Leander, J. D., Stanton, P. K., et al. (2013). GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38, 729-742. doi: 10.1038/npp.2012.246.
9. Carrier, N., and Kabbaj, M. (2013). Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 70, 27-34. doi: 10.1016/j.neuropharm.2012.12.009.
10. Chalecka-Franaszek, E., and Chuang, D. M. (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U.S.A. 96, 8745-8750. doi: 10.1073/pnas.96.15.8745.
11. Chiu, C. T., Scheuing, L., Liu, G., Liao, H. M., Linares, G. R., Lin, D., et al. (2014). The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int. J. Neuropsychopharmacol. 18:pyu102. doi: 10.1093/ijnp/pyu102.
12. Cipriani, A., Pretty, H., Hawton, K., and Geddes, J. R. (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am. J. Psychiatry 162, 1805-1819. doi: 10.1176/appi.ajp.162.10.1805.
13. Collaborators, U. S. B. O. D. (2013). The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 310, 591-608. doi: 10.1001/jama.2013.13805.
14. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789. doi: 10.1038/378785a0.
15. Da Silva, F. C., Do Carmo De Oliveira Cito, M., Da Silva, M. I., Moura, B. A., De Aquino Neto, M. R., Feitosa, M. L., et al. (2010). Behavioral alterations and pro-oxidant effect of a single ketamine administration to mice. Brain Res. Bull. 83, 9-15. doi: 10.1016/j.brainresbull.2010.05.011.
16. De Oliveira, L., Spiazzi, C. M., Bortolin, T., Canever, L., Petronilho, F., Mina, F. G., et al. (2009). Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1003-1008. doi: 10.1016/j.pnpbp.2009.05.010.
17. Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., et al. (2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67, 793-802. doi: 10.1001/archgenpsychiatry.2010.90.
18. Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., et al. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112, 257-269. doi: 10.1016/S0092-8674(03)00035-7.
19. Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., et al. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71, 681-688. doi: 10.1001/jamapsychiatry.2014.62.
20. Fenton, T. R., and Gout, I. T. (2011). Functions and regulation of the 70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 43, 47-59. doi: 10.1016/j.biocel.2010.09.018.
21. Feyissa, A. M., Chandran, A., Stockmeier, C. A., and Karolewicz, B. (2009). Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 70-75. doi: 10.1016/j.pnpbp.2008.10.005.
22. Freland, L., and Beaulieu, J. M. (2012). Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front. Mol. Neurosci. 5:14. doi: 10.3389/fnmol.2012.00014.
23. Gao, Y., Romero-Aleshire, M. J., Cai, Q., Price, T. J., and Brooks, H. L. (2013). Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells. Am. J. Physiol. Renal Physiol. 305, F1201-1208. doi: 10.1152/ajprenal.00153.2013.
24. Garcia, L. S., Comim, C. M., Valvassori, S. S., Reus, G. Z., Barbosa, L. M., Andreazza, A. C., et al. (2008). Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 140-144. doi: 10.1016/j.pnpbp.2007.07.027.
25. Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., et al. (2001). Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864. doi: 10.1101/gad.912401.
26. Gunduz-Bruce, H. (2009). The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res. Rev. 60, 279-286. doi: 10.1016/j.brainresrev.2008.07.006.
27. Hashimoto, R., Fujimaki, K., Jeong, M. R., Christ, L., and Chuang, D. M. (2003). Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. FEBS Lett. 538, 145-148. doi: 10.1016/S0014-5793(03)00167-4.
28. Hashimoto, R., Hough, C., Nakazawa, T., Yamamoto, T., and Chuang, D. M. (2002). Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J. Neurochem. 80, 589-597. doi: 10.1046/j.0022-3042.2001.00728.x.
29. Insel, T. R., and Wang, P. S. (2009). The STAR*D trial: revealing the need for better treatments. Psychiatr. Serv. 60, 1466-1467. doi: 10.1176/ps.2009.60.11.1466.
30. Jernigan, C. S., Goswami, D. B., Austin, M. C., Iyo, A. H., Chandran, A., Stockmeier, C. A., et al. (2011). The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1774-1779. doi: 10.1016/j.pnpbp.2011.05.010.
31. Kavalali, E. T., and Monteggia, L. M. (2012). Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am. J. Psychiatry 169, 1150-1156. doi: 10.1176/appi.ajp.2012.12040531.
32. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., et al. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175. doi: 10.1016/S0092-8674(02)00808-5.
33. Krystal, J. H., D'souza, D. C., Mathalon, D., Perry, E., Belger, A., and Hoffman, R. (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacol. (Berl). 169, 215-233. doi: 10.1007/s00213-003-1582-z.
34. Krystal, J. H., Perry, E. B. Jr., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., et al. (2005). Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry 62, 985-994. doi: 10.1001/archpsyc.62.9.985.
35. Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., et al. (2012). Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol. Psychiatry 72, e27-e28. doi: 10.1016/j.biopsych.2012.05.031.
36. Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., and Zarate, C. A. (2014). Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl. Psychiatry 4, e469. doi: 10.1038/tp.2014.105.
37. Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., and Duman, R. S. (2014). BDNF release is required for the behavioral actions of ketamine. Int. J. Neuropsychopharmacol. 18:pyu033. doi: 10.1093/ijnp/pyu033.
38. Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964. doi: 10.1126/science.1190287.
39. Li, N., Liu, R. J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., et al. (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69, 754-761. doi: 10.1016/j.biopsych.2010.12.015.
40. Liu, R. J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., and Aghajanian, G. K. (2013). GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 38, 2268-2277. doi: 10.1038/npp.2013.128.
41. Liu, R. J., Lee, F. S., Li, X. Y., Bambico, F., Duman, R. S., and Aghajanian, G. K. (2012). Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71, 996-1005. doi: 10.1016/j.biopsych.2011.09.030.
42. Maeng, S., Zarate, C. A. Jr., Du, J., Schloesser, R. J., Mccammon, J., Chen, G., et al. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349-352. doi: 10.1016/j.biopsych.2007.05.028.
43. Monteggia, L. M., and Zarate, C. Jr. (2015). Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr. Opin. Neurobiol. 30, 139-143. doi: 10.1016/j.conb.2014.12.004.
44. Murray, C. J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., et al. (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2197-2223. doi: 10.1016/S0140-6736(12)61689-4.
45. Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., et al. (2013a). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170, 1134-1142. doi: 10.1176/appi.ajp.2013.13030392.
46. Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., Aan Het Rot, M., et al. (2013b). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry 74, 250-256. doi: 10.1016/j.biopsych.2012.06.022.
47. Ng, F., Berk, M., Dean, O., and Bush, A. I. (2008). Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 11, 851-876. doi: 10.1017/S1461145707008401.
48. Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., and Kavalali, E. T. (2013). Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J. Neurosci. 33, 6990-7002. doi: 10.1523/JNEUROSCI.4998-12.2013.
49. Park, S. W., Lee, J. G., Seo, M. K., Lee, C. H., Cho, H. Y., Lee, B. J., et al. (2014). Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons. Int. J. Neuropsychopharmacol. 17, 1831-1846. doi: 10.1017/S1461145714000534.
50. Petryshen, T. L., Sabeti, P. C., Aldinger, K. A., Fry, B., Fan, J. B., Schaffner, S. F., et al. (2010). Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 15, 810-815. doi: 10.1038/mp.2009.24.
51. Popik, P., Kos, T., Sowa-Kucma, M., and Nowak, G. (2008). Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacol. (Berl). 198, 421-430. doi: 10.1007/s00213-008-1158-z.
52. Price, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., et al. (2014). Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress. Anxiety 31, 335-343. doi: 10.1002/da.22253.
53. Price, R. B., Nock, M. K., Charney, D. S., and Mathew, S. J. (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66, 522-526. doi: 10.1016/j.biopsych.2009.04.029.
54. Rapoport, S. I. (2014). Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem. Neurosci. 5, 459-467. doi: 10.1021/cn500058v.
55. Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., et al. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38, 2475-2483. doi: 10.1038/npp.2013.150.
56. Sanacora, G., and Schatzberg, A. F. (2015). Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 40, 1307. doi: 10.1038/npp.2014.338.
57. Sarandol, A., Sarandol, E., Eker, S. S., Erdinc, S., Vatansever, E., and Kirli, S. (2007). Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum. Psychopharmacol. 22, 67-73. doi: 10.1002/hup.829.
58. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302. doi: 10.1016/j.cub.2004.06.054.
59. Sarbassov, D. D., Ali, S. M., and Sabatini, D. M. (2005). Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603. doi: 10.1016/j.ceb.2005.09.009.
60. Sutherland, C., Leighton, I. A., and Cohen, P. (1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296(Pt 1), 15-19.
61. Trullas, R., and Skolnick, P. (1990). Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185, 1-10. doi: 10.1016/0014-2999(90)90204-J.
62. Yasuda, S., Liang, M. H., Marinova, Z., Yahyavi, A., and Chuang, D. M. (2009). The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 14, 51-59. doi: 10.1038/sj.mp.4002099.
63. Yilmaz, A., Schulz, D., Aksoy, A., and Canbeyli, R. (2002). Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochem. Behav. 71, 341-344. doi: 10.1016/S0091-3057(01)00693-1.
64. Zarate, C. A. Jr., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., et al. (2012b). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71, 939-946. doi: 10.1016/j.biopsych.2011.12.010.
65. Zarate, C. A. Jr., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L., Ramamoorthy, A., et al. (2012a). Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol. Psychiatry 72, 331-338. doi: 10.1016/j.biopsych.2012.03.004.
66. Zarate, C. A. Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864. doi: 10.1001/archpsyc.63.8.856.
67. Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M. M., and Pariante, C. M. (2013). Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol. Psychiatry 18, 1236-1241. doi: 10.1038/mp.2013.87.
68. Zuo, D. Y., Wu, Y. L., Yao, W. X., Cao, Y., Wu, C. F., and Tanaka, M. (2007). Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacol. Biochem. Behav. 86, 1-7. doi: 10.1016/j.pbb.2006.05.010.